First-Ever Year-Long Continuous Glucose Monitor Exciting, Holds Promise

Last year, the FDA approved use of the Eversense 365 year-long continuous glucose monitor (CGM) and approved its use with insulin pumps. Eversense 365 is the first CGM to work for as long as a year and is approved for those with type 1 diabetes mellitus 18 years or older. Other CGMs on the market typically last for one to two weeks.

“A year-long sensor is really exciting, especially paired with an insulin pump,” says Sarah D. Crimmins, D.O., an associate professor of obstetrics and gynecology at University of Rochester School of Medicine & Dentistry and the program director of DPSG-NA.

From a patient standpoint, not having to replace a CGM every seven days to two weeks results in one less thing to worry about.

From a provider standpoint, Crimmins finds Eversense’s online tools to review the patient’s history are less commonly encountered than other CGMs. “We will need to continue adapting to new technology and collaborating as a team to ensure that all members can review and respond to the latest data.” says. As with all newer technologies, as adoption increases, the learning curve will decrease.

“All said, technology for managing type 1 diabetes is heading in the right direction in making the patients’ lives easier, and that’s what matters most.”